About the Study: For patients with breast cancer receiving injectable gonadotropin-releasing hormone agonist therapy, a home injection model supported by telemedicine reduced treatment burden by improving convenience and saving time for many participants. Most patients who completed home injections chose to continue this approach beyond the pilot. Barriers such as insurance denials and higher copayments for at-home administration may limit broader implementation.
JAMA+ Women's Health
Explore JAMA+ Women's Health for more Women's Health research, commentary, multimedia, and resources from across JAMA Network.
Led by Editor in Chief Linda Brubaker, MD, JAMA+ Women's Health is a curated source of trusted clinical information that advances health care for women worldwide. Dr Brubaker is also a JAMA Deputy Editor.
